biotech

Female patient on gurney

Recro Pharma Files for Secondary Offering Following Big Late-Stage Win

Recro Pharma Inc. (NASDAQ: REPH) saw its shares fall on Thursday after the company announced a secondary offering. No pricing details were given in the filing, but the offering is ...
Read Full Story »
IPO

TiGenix Closes in on IPO

TiGenix has filed an amended F-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company did not give any pricing details in ...
Read Full Story »
blue eye

Clearside Biomedical Gears Up for Secondary Offering

Clearside Biomedical Inc. (NASDAQ: CLSD) has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering. The company did not give any pricing ...
Read Full Story »
FDA_logo

FDA Requests Additional Data on Amicus’ Fabry Disease Treatment

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is watching its shares drop on Tuesday after the company provided an update on its regulatory pathway for its Fabry Disease treatment. After the company ...
Read Full Story »
doctor

Genetic Technologies Practically Doubles on Licensing Agreement

Shares of Genetic Technologies Ltd. (NASDAQ: GENE) practically doubled in Tuesday’s session following a key licensing agreement. The company announced the signing of an exclusive worldwide license agreement with the University ...
Read Full Story »
FDA_logo

PhaseRx More Than Doubles on Key FDA Approval

Shares of PhaseRx Inc. (NASDAQ: PZRX) more than doubled on Monday after the company announced that it received a key U.S. Food and Drug Administration (FDA) approval. The company announced ...
Read Full Story »
biotech word cloud

Short Sellers Grow More Aggressive on Major Biotechs

The short interest data are out for the most recent settlement date, November 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »
tired frustrated unhappy business person

Juno Falls Sharply on Self-Imposed Clinical Hold

Juno Therapeutics Inc. (NASDAQ: JUNO) saw its shares hit a new 52-week low in Wednesday’s session after the company announced a clinical hold on its JCAR015 trial. The company announced ...
Read Full Story »
FDA_logo

Oragenics Practically Doubles on FDA Decision

Oragenics Inc. (NYSEMKT: OGEN) saw its shares practically double late on Monday, and even continue climbing after the trading session ended, following an update from the U.S. Food and Drug ...
Read Full Story »
tired frustrated unhappy business person

Acorda Slides on Clinical Study Update

Acorda Therapeutics, Inc. (NASDAQ: ACOR) is watching its shares slide on Monday after the company gave an update on a recent clinical study. Essentially, the company announced that its Milestone ...
Read Full Story »
biotech word cloud

Why NovoCure Shares Could Double, or Rise Even More

With the market effectively at all-time highs after the election, investors are looking for new ideas to generate income or gains ahead. Sometimes investors turn to Wall Street research to ...
Read Full Story »
cancer

BeiGene Prices Secondary Offering

BeiGene Ltd. (NASDAQ: BGNE), which entered the market back in February, has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering. The ...
Read Full Story »
IPO

AnaptysBio Files for IPO

AnaptysBio has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing. The company intends ...
Read Full Story »
One US dollar banknote closeup

Synthetic Biologics Prices Secondary Offering

Synthetic Biologics Inc. (NYSEMKT: SYN) has just announced the pricing for its secondary offering. The company expects to price its 25 million shares and warrants to purchase 50 million at ...
Read Full Story »
child with cancer

BeyondSpring Gears Up for IPO

BeyondSpring has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company did not list and pricing details in the filing, ...
Read Full Story »